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Abstract
Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous neoplasm associated with a high cure rate. We
present a case of aggressive DFSP with fibrosarcomatous areas in the head and neck. A 28-year-old Mediterranean
female presented with a 45-day history of rapidly growing cutaneous lesion of the face. Surgical biopsy confirmed
the diagnosis of DFSP. Subsequently, the patient underwent wide local surgical resection, followed by
reconstruction. Histopathology report revealed fibrosarcomatous transformation and the patient underwent
adjuvant radiotherapy. The patient continues to be disease free at the 35-month follow-up.
Although DFSP behave as non-aggressive malignancy, surgery with complete removal of the affected area is the
intervention of choice. Moreover, adjuvant treatment and follow-up of the patient is essential in order to prevent
recurrence.
Introduction
Dermatofibrosarcoma protuberans (DFSP) is a locally
aggressive, cutaneous, malignant tumor characterized by
high propensity for local relapse and low metastatic
potential. It was first recognized by Taylor [1] in 1890,
and described by Darrier [2] in 1924, but the term “der-
matofibrosarcoma protuberans” was coined by Hoffman
[3] in 1925. It has been reported to involve many body
surfaces, mainly the trunk (42-72%), followed by the
extremities (16-30%) and less commonly in the head
and neck (10-16%) [4]. Although it constitutes less than
0.1% of all malignant neoplasms, it represents the most
frequent skin sarcoma (nearly 1% of all soft tissue sarco-
mas), more than 1% of all head and neck malignant
tumours and 7% of all head and neck sarcomas [5,6].
Approximately 85-90% of all DFSPs represent low-
grade tumours. The remaining 10-15% contains a com-
ponent of high-grade fibrosarcoma. This transformation,
presenting in more than 5% of tumour volume, is
characterized by a higher incidence of local relapse and
distance metastasis.
The characteristic villous pattern of extension into the
subcutaneous fat, fascia and muscles and at the same
time preservation of healthy tissue from resection repre-
sents a surgical challenge, as failure of complete excision
leads to local recurrence. We report a rare case of an
aggressive head and neck DFSP with fibrosarcomatous
areas. We also discuss the epidemiology, clinical and
pathologic characteristics and treatment.
Case report
A 28-year-old Mediterranean female with unremarkable
medical history, attended the out-patients department,
with a 45-day history of a painless rapidly growing
lesion in the right cheek (infra-auricular area). Clinical
examination revealed a protruding painless red-bluish
mass, which was associated with the skin over the paro-
t i da r e a .T h el e s i o n( s i z e d1 0×5×4c m )w a sf i r m ,
fixed to deeper tissues with propensity to bleed. No
facial nerve involvement was noted (Figure 1).
Ultrasonographic examination revealed a well vascu-
larized mass infiltrating the subcutaneous fat and the
parotid. Computed tomographic and magnetic reso-
nance imaging evaluation revealed a parotid mass fixed
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skin; multiple small lymph nodes involvement along the
jugular vein were also noted (Figures 2 and 3). No dis-
tant metastasis was reported. Fine needle aspiration
cytology reported a mesenchymal lesion; incisional
(true-cut) biopsy, under local anesthesia showed a possi-
ble grade II sarcoma (storiform malignant fibrous
histiocytoma).
The decision was made, in a multi-disciplinary
meeting, to treat the tumour with wide local resection.
This involved a superficial parotidectomy and selective
neck dissection (levels II-V). The defect was recon-
structed with a large neck pedicle advancement flap
(Figure 4).
Histopathological examination, of the completely
excised tumour, revealed a nodular neoplastic lesion
composed of large spindle-shaped cells with prominent
nuclei, showing a high mitotic index and areas of necro-
sis, infiltrating into the subcutaneous fat and muscles
(Figure 5). Further immunohistochemical analysis
revealed tumour cells which were positive for CD34,
and c-kit antigen. A few cells were positive for SMA
Figure 1 Clinical image showing an infra-auricular lesion (10 ×
5 × 4 cm in size).
Figure 2 Computed tomography image showing a parotid
mass adherent to overlying skin.
Figure 3 Magnetic resonance image showing a soft tissue
mass associated with the parotid gland.
Figure 4 Postoperative image following local excision and
reconstruction.
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tive cells and increased mitotic rate (>20/10 HPFs). It
was concluded that this constellation of staining repre-
sented a “dermatofibrosarcoma protuberans with fibro-
sarcomatous transformation” (Figure 6).
Following the diagnosis, the multi-disciplinary team
decided that an adjuvant therapy would be required. The
patient, subsequently, received 60 Gy of radiation therapy
and subsequent recovery was unremarkable. At 35-month
post-treatment follow-up, the patient continues to be
symptom free with no signs of tumour recurrence.
Discussion
Epidemiology
The estimated incidence of DFSP is 4.5 cases per million
persons per year in the USA [7], nearly 3 in France [8]
and 4 in Sweden [9]. In some studies, a slight male pre-
dominance (55-57%) [10,11] has been reported, although
in others no gender predilation was established [7]. The
incidence among Afroamericans compared to Cauca-
sians is almost double (6.5 vs 3.9 per million) [12]. It
affects almost every age. Although, it appears predomi-
nantly in adults (20-50 years) it has also been reported
in children [13-16]. No evidence of hereditary or familial
predisposition exists. The 5-year relative survival rates
for reported in all population-based studies are can
reach up to 100% [7,8,12].
Macroscopically
DFSP is a dermis origin cutaneus neoplasm character-
ized by slow infiltrative growth with a tendency for local
relapse, after surgical excision, with little metastatic
potential. Clinically the appearance of the tumour
depends on the stage of the disease. Initially it presents
as a cutaneous pink to red-bluish painless trophic and/
or sclerotic plaque-like mass that develops into lumpy
nodular and over time into ulcerative hemorrhagic pro-
tuberant tumor. It develops superficially, mobile upon
palpation as it is adhered with its overlying skin, but not
with its underlying tissues. Unfortunately, fixation to
deeper structures such as fascia and muscle may present
in the later stage of the tumour. Scalp fixation caused
by periosteal attachment may occur in early stages. Tel-
angiectasia may be apparent on the surface or at the
periphery.
Since it is a slow growing tumor, the duration of
development range from weeks to years. Delay in diag-
nosis and clinical misdiagnosis of the initial lesion is not
uncommon, and is due to absence of symptoms. Pain
and tenderness are rare, as only 10-25% of the patients
reported these symptoms. In addition cachexia which
usually characterizes advanced malignancies is also
uncommon [5]. Differential diagnosis in the initial stages
should include lipomas, epidermal cysts, keloid and nod-
ular fasciitis. In late stages, when it becomes protuberant
it should be differentiated from pyogenic granuloma and
other soft tissue sarcomas.
Histopathology
The true cellular origin of this neoplasm is yet unclear.
Evidence exists that its origin may be fibroblastic, neu-
roectodermal, histiocytic or from pluropotential progeni-
tor cells that have the capacity to differentiate into these
three cell-types. Microscopically it is characterized by
the arrangement of spindle-shaped tumor cells in a
“cartwheel” pattern [17], cytologically monomorhous
bland spindle cells, with a characteristic finger-like, hon-
eycomb pattern of infiltration into the subcutaneous fat.
These neoplastic projections, like pseudopodia may eject
up to 3 cm peripherically.
Figure 5 Histopathology image showing dermatofibrosarcoma
protuberans. (a) H&E ×10 spindle-shaped tumor cells in a
“cartwheel” pattern. (b) H&E ×40 showing increase number of mitosis.
Figure 6 Histopathology image showing immunopositivity to
CD34. (a) ×25 showing immunopositivity to CD34. (b) ×40 showing
immunopositivity to CD34.
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positivity for CD34 (sensitivity 84-100%) and vimentin
and negativity for S-100, factor XIIIa and CD44 staining.
Positivity of this last marker and stromelycin 3 (ST3) is
useful for differential diagnosis of benign fibrous histiocy-
toma (dermatofibroma) [18]. Apolipoprotein D has also
been described as a marker for DFSP, as West et al. [19]
in 2004 concluded, that it is strongly expressed in DFSPs
and neural lesions and may be useful in differentiating
DFSP from benign fibrous histiocytoma (dermatofi-
broma). The differential diagnosis should also include
malignant fibrous histiocytoma, atypical fibroxanthoma,
diffuse neurofibroma, giant cell fibroblastoma, myxoid
liposarcoma, myxofibrosarcoma and desmoplastic
melanoma [5].
Bendar or pigmented DFSP represents an unusual var-
iant distinguished by the dispersal of melanin-containing
dendritic cells in an otherwise typical DFSP. It accounts
less than 5% of all DFSP cases predominantly occur in
Afroamericans (7.5 times higher than Caucasians).
Other unusual histologic types include myxoid, giant
cell angiofibroma, granular cell variant DFSP, palisaded
(reminiscent of schwannoma), sclerosing and the
atrophic type.
A more aggressive subtype presents with fibrosarco-
matous progression is called “fibrosarcomatous dermato-
fibrosarcoma” (FS-DFSP). Firstly reported by Penner
[20] in 1951 to represent a component of intermediate
to high grade sarcoma, with more spindle cells, greater
number of nuclei and increased mitotic rate compared
to “classic” DFSP(median: 20 vs. 2 mitoses/HPFs),
immunohistochemically demonstrating a decrease of
CD34. It is regarded as a rare lesion with approximately
50 cases reported until 1998 [21]. It appears in approxi-
mately 10-15% of DFSP cases, characterized by a higher
incidence of local relapse and distance metastasis.
According to Mentzel et al. [21] progression of DFSP to
FS-DFSP may represent “dedifferentiation” and Abbott
et al. [22] demonstrated that “FS change in DFSP repre-
sents a form of tumor progression with increased risk of
metastasis over classic DFSP, associated with gains of
p53 mutations and increased proliferative activity”.
Molecular Pathogenesis
Although an injury to the affected skin, such as surgical
and old burn scars and sites of vaccinations may be pre-
disposing factors for PDFS development [17,23], its
cause is yet unknown. More than 90% of DFSP are char-
acterized by reciprocal chromosomal translocation
between chromosomes 17 and 22, t(17;22) or supernu-
merary ring chromosomes composed of interspersed
sequences from bands 17(17q22) and 22(22q12). It is
now clear that this fusion is the main abnormality in its
molecular identity. This chromosome rearrangement
fuses the strongly expressed collagen 1-Alpha-1gene
(COL1A1) on chromosome 17 with the platelet derived
growth factor (PDGF-B) gene on chromosome 22.
PDGF-B, which is a potent mitogen for connective
tissue cells, is placed under the control of COL1A1 pro-
moter. This results in autocrine activation of the platelet
derived growth factor receptor tyrosine kinase (PDGF-R)
which triggers the proliferation of DFSP tumor cells.
Staging
Since clinical diagnosis of the initial lesion is not always
possible with certainty, open biopsy, excisional or inci-
sional, is the diagnostic method of choice. Imaging
using MRI to evaluate local extension is essential for the
preoperative planning of large tumors and computed
tomography is useful only when underlying bone ero-
sion is suspected. Ultrasonographic examination may
also be useful, mainly in detecting small lesions.
Although lymphatic and hematogenous metastasis is
uncommon, staging is always indicated.
The American Joint Committee on Cancer has not yet
set a system for the staging of DFSPs and DFSP-FSs.
Until today it is in accordance with the American Mus-
culoskeletal Tumor Society (MSTS) staging system,
which takes into account tumor grade and compartmen-
talization: In stage IA tumors are low-grade intracom-
partmental (without extension beyond the subcutaneous
compartment) lesions, that can be managed adequately
solely with wide excision. In stage IB tumors are again
low-grade lesions that exhibit extracompartmental
extension, which involves the underlying fascia, muscle,
or bone erosion [24]. More recently, Ugurel et al. [25]
proposed a staging system according to German Guide-
l i n e sf o rD F S P .I nt h i ss y s t e ms t a g eIr e p r e s e n tt h ep r i -
mary tumor stadium, stage II describes a DFSP with
regional lymph node metastases and stage III charac-
terizes distance metastases.
Treatment and Prognosis
DFSPs show an extremely aggressive tendency to invade
local surrounding tissue. Standard therapeutic approach
used for the treatment of this tumor is wide and deep
local excision (WLE), including the underlying fascia. In
a retrospective study of 159 cases, although 99% of the
cohort had complete surgical resection, pathologic
review showed only 93 patients (58%) with negative
microscopic margins [11]. Lindner et al. [26] reported
that 2.5-3.5 cm circumferential removal of healthy tis-
sues improved local control of the disease. It is yet gen-
erally agreed that 3-5 cm lateral and deep margins are
adequate for the local control of the disease.
In order to achieve negative resection margins and
simultaneously preserve the uninvolved tissue from
resection, some authors suggest the use of Moh’s
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cise histological mapping of all margins, both deep and
lateral. Classic technique requires continuing sequential
horizontal sectioning during resection and immediate,
frozen, microscopic examination, until free margin is
obtained. Although ideal, especially for challenging areas
such as head and neck region, it may be proven inade-
quate predictor of final resection margin status. A study
involving intraoperative assessment of frozen sections
concluded that accuracy was low - 80% (16 out of 20)
[6]. On the other hand the modified method, using par-
affin-embedded sections, is a more accurate but at the
same time, a very elaborated and time-consuming. The
largest single centre published series on outcomes of
DFSP, demonstrated that WLE with reconstruction can
give disease control in nearly 90% of the cases [27]. In
contrast to Paradisi et al. [28] in a study of 79 patients
treated with WLE (n = 38) or MMS (n = 41) between
1990-2005 established 13.2% local recurrence rate (5/38
patients, 95% CI 4.4-28.1%, follow-up of 4.8 years) and
none (95% CI 0-8.6%, follow-up of 5.4 years), respec-
tively. In the same study a review of the literature
yielded 6/463 recurrences for MMS (1.3%, 95% CI 0.5-
2.8%) and 288/1394 recurrences for WLE (20.7%, 95%
CI 18.6-22.9%).
Since primary closure is not always feasible, recon-
structive surgery, using local skin flap, skin grafting,
mesh or myocutaneus flap may be required. Neck dis-
section is not necessary unless suspicious regional lym-
phadenopathy is present. Only in FS-DFSP cases
sentinel lymphnode biopsy is recommended.
Local Recurrence
The most significant prognostic factor for relapse has
proved to be the extent of the initial resection as close
margins (<2 cm) shows a statistically significant positive
correlation with recurrence. Rutgers et al. [10] in an
extensive review of 913 DFSP cases in the literature
reported nearly 50% overall recurrence rate decreasing
to 13% after adequate wide excision. Lemm et al. [4] in
their review of the literature established a 39.7% total
recurrence rate in 116 patients with undefined or con-
servative surgical margins. In the same review the total
recurrence rate of 661 patients underwent WLE was
decreased to 8.8%. In a similar analysis of the literature,
Gloster et al. [29] reported 43% recurrence rate in a
review of 317 patients and 18% in a review of 489
patients respectively. Moreover, in the largest monoin-
stitutional series of DFSP, in Italy, all 218 patients were
treated with WLE and reconstructive surgery, 10 year
local relapse incidence was 4% [27]. In contrast, a recent
study of 204 patients treated with WLE with relatively
narrow margins of 1-2 cm, established an incidence of
5-year local relapse of only 1%, recognizing that addi-
tional follow-up may increase it [30].
The Head and neck region is reported to be the site
with the highest rate of local recurrence rate (LRR) after
local excision. Barnes et al. [31] reported 17 personal
cases of head and neck DFSP (HN-DFSP) with 53%
LRR. Same authors in a review of the literature estab-
lished 73% LRR in a series of 92 patients. Mark et al.
[32] also reported very high LRR (60%) in a series of 16
patients suffering HN-DFSP. Although Stojadinovic et
al. [6] reported a “normal” LLR of 9% in their series of
33 patients with HN-DFSP, 12 of these patients (36%)
presented in their centre with already recurrent disease,
after prior local excision elsewhere. In addition, in
Farma’s [30] recent study of 204 DFSP cases, the only
two local recurrences reported in the head and neck. It
is understood that head and neck surgeons are more
conservative due to the critical structures of the area
and the cosmetic difficulties in reconstruction of the
surgical defect. On the other hand multiple recurrences
caused by inadequate control of the initial disease pre-
disposes to distant metastasis and poor outcome [10].
FS-DFSP subtype is also considered to be a highly sig-
nificant prognostic factor for relapse. In a large prospec-
tive analysis of 159 patients, 13 of 25 patients (52%)
with FS-DFSP experienced relapse versus 21 of 134
patients (16%) with classic DFSP. In the same analysis
the 5-year recurrence free survival rates were 81% for
patients with DFSP and only 28% for those with FS-
DFSP subtype [11]. In addition in Mentzels study [21],
follow up of 34 from 41 FS-DFSP patients revealed local
relapse in 20 patients (58%). Only Goldblum et al.
[ 3 3 ]a n dA b b o t te ta l .[ 2 2 ]r e f e r r e dl o w e rL L R( 2 2 %
and 20%) in a series of 17 and 41 FS-DFSP cases
respectively.
Other unfavorable prognostic factors for local and dis-
tance relapse, represents age older than 50 years, high
mitotic rates and increased cellularity. Regional lympha-
tic metastasis is uncommon, approximately 1%, even
less frequent than distant metastasis with only a few
cases reported in the literature up to date [10,34].
Distance Metastasis
Although very rare, DFSP do metastasize, principally to
the lungs and bones. Rutgers et al. [10] reported 37
metastases (4%) in a review of 913 cases in the litera-
ture. Earlier Das Gupta [35] reported 27 cases (5.7%)
after reviewing 475 cases in the literature. In contrast
Bowne et al. [11] referred a metastatic rate of only 1%
(2 out 159 patients). Interestingly these 2 patients, both
succumbed to their disease, suffered from FS-DFSP,
representing 8% (2 out of 25 patients) metastatic rate in
this subtype. Also in the largest monoinstitutional series
of 218 patients suffering DFSP (211 classic and 7 FS-
DFSP) treated with wide local excision, the incidence of
10 year metastasis was low (2%, 5 patients). Again from
the 7 patients suffering FS-DFSP, 2 (28%) developed and
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one of them without prior local recurrence [27].
Furthermore Ding et al. [36] focused on FS-DFSP
tumours, reviewed 21 cases and established an overall
metastatic rate of 14.3% (3 patients). In addition Menzel
et al. [21] reported similar metastatic rate (14.7%, 5 out
of 41 FS-DFSP patients), all pulmonary, one with addi-
tional soft tissue and one with additional multiple oss-
eous metastases. Two of these patients (5.8%) died from
disease progression. Same author in a review of the lit-
erature reported another 6 cases (13%) of metastases
and 11% of tumour-related death concluding that
F S - D F S Ps h o u l db ed e s i g n a t e da saf u l l ym a l i g n a n ts o f t
tissue neoplasm in contrast with classic DFSP. A more
recent series of FS-DFSP from a single institution
also evaluated high metastatic rate (10%, 4 out of
41 patients) [22]. In this study one patient experienced
pulmonary and osseous metastases, 2 pulmonary and
one osseous metastasis. Two of these patients (5%) suc-
cumbed to their disease. In contrast Goldblum et al.
[33] in their analysis of 17 cases of FS-DFSP with at
least five years follow-up reported no metastatic disease
in patients treated with wide local excision.
Conservative Treatment
In the past, radiotherapy (RT) was considered to have
limited role in treatment of this disease. Recently pub-
l i s h e dd a t ad e m o n s t r a t e dt h a tD F S Pi sar a d i o s e n s i t i v e
tumour. An analysis of 10 cases, 9 DFSP and 1
FS-DFSP, established 90% local control of the disease,
concluding that adjuvant radiotherapy reduces the risk
of local relapse after resection of the disease in close or
positive margins. Interestingly, 60% (6 patients) of these
cases were located in the head & neck and the patient
suffering from FS-DFSP, also located in head and neck,
was the one who experienced the local recurrence after
3 months and died from the disease [37]. Similarly Sun
et al. [38] in a series of 35 patients, 24 treated surgically
and 11 with surgery and RT, reported 7-year local con-
trol rates of 28% and 80% respectively.
Preferably the excision shou l df o l l o w e db ya d j u v a n t
radiotherapy, when margins are found close or persistently
positive and repeat wider resection is not feasible due to
anatomic limitations. Some authors also recommend the
use of radiotherapy after wide resection in the fibrosarco-
matous subtype, even with negative margins [30]. German
guidelines for DFSP treatment suggests 60 and 70 Gy for
micro- and macroscopic disease, respectively, including
primary tumor, postoperative scars and a safety margin of
3-5 cm and palliative dosage of 50 Gy [25].
Although chemotherapy is proved to be ineffective,
recently targeted therapy has shown very good results in
disseminated cases. Imatinib mesylate, a selective tyro-
sine kinase inhibitor designed to treat chronic myelo-
genous leukaimia, resulted also in inhibiting PDGFR
tyrosine kinase that plays a crucial role in the pathogen-
esis and tumor growth of DFSP cells.
A phase II study published in 2005, reported 100%
response in 8 local advanced DFSPs, partial response in
a metastatic FS-DFSP, all with t(17;22) translocation and
no clinical response in another metastatic FS-DFSP lack-
ing t(17;22), correlating the presence of this transloca-
tion with response. All patients were treated with 400
mg of imitinib twice daily, well tolerated, decreasing
dosage into 600 mg in only one patient [39]. It is gener-
ally accepted that the use of this drug is indicated in
patients with unresectable, locally advanced, recurrent
or metastatic disease. It can also be used in tumor
shrinkage prior to surgery, avoiding loss of functions
and cosmetic defects. A recent study reported tumour
size reduction and decreased cellularity after preopera-
tive treatment with imatinib [40]. More studies are
needed to determine whether it could play a role in
neoadjuvant setting.
Conclusion
D F S Pi sar a r ed e r m a lm a l i g n a n c yw i t hap r o p e n s i t yt o
be locally aggressive but rarely metastatic. Its fibrosarco-
matous progression variant on the other hand has a
more aggressive course in nature, with a significant ele-
vated risk of both local and distance metastasis, usually
followed by poor outcome.
Wide local excision is the gold standard treatment and
a policy of re-excision to obtain negative margins should
always be followed. One of the most challenging areas is
the head and neck, with increased rate of local failure,
due to critical structures and aesthetic difficulties in
reconstruction.
We reported a case of an aggressive head and neck
FS-DFSP, treated with wide local resection and adjuvant
radiotherapy, without evidence of local or distance
relapse after 35 months. Follow-up, even lifelong,
remain essential.
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